JournalsHub
.online
Find My Journal
MU

M. Untch

Goethe University Frankfurt DE

63
Publications
459
Citations
8
H-Index
8
i10-Index
15.06
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013) OA
M. Untch, Bernd Gerber, Nadia Harbeck, Christian Jackisch, Norbert Marschner +26 more
Breast Care 2013
131
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer OA
Charles E. Geyer, M. Untch, Chiun‐Sheng Huang, Max S. Mano, Eleftherios P. Mamounas +29 more
New England Journal of Medicine 2025
92
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial OA
Gabriel N. Hortobágyi, Aleksandra Łacko, Joohyuk Sohn, F. Melo Cruz, Manuel Ruíz Borrego +24 more
Annals of Oncology 2024
79
58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
Frederik Marmé, Claus Hanusch, Jenny Furlanetto, Patrick G. Morris, T. Link +15 more
Annals of Oncology 2022
29
Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping OA
Carsten Denkert, Sivaramakrishna Rachakonda, Thomas Karn, Karsten E. Weber, Miguel Martín +35 more
Cancer Cell 2025
21

Publications

57 total

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer PDF

Charles E. Geyer, M. Untch, Chiun‐Sheng Huang, Max S. Mano, Eleftherios P. Mamounas et al. - New England Journal of Medicine, 2025
Cited by 92 OpenAlex

Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping PDF

Carsten Denkert, Sivaramakrishna Rachakonda, Thomas Karn, Karsten E. Weber, Miguel Martín et al. - Cancer Cell, 2025
Cited by 21 OpenAlex

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

Sibylle Loibl, Yeon Hee Park, Zhi‐Ming Shao, Chiun‐Sheng Huang, Carlos Barrios et al. - New England Journal of Medicine, 2025
Cited by 14 OpenAlex

Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers PDF

Lothar Häberle, Ramona Erber, Paul Gaß, Alexander Hein, Melitta Niklos et al. - Breast Cancer Research, 2025
Cited by 8 OpenAlex

AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025 PDF

Toralf Reimer, Thorsten Kuehn, Volkmar Mueller, Nina Ditsch, Tanja Fehm et al. - European Journal of Surgical Oncology, 2025
Cited by 7 OpenAlex

Behandlung von Patientinnen mit frühem Mammakarzinom

M. Untch, M. Banys-Paluchowski, S. Brucker, C. Denkert, P. Fasching - Senologie - Zeitschrift für Mammadiagnostik und -therapie, 2025
Cited by 0 Semantic Scholar

Medikamentöse Therapie des frühen Mammakarzinoms

D. Lüftner, M. Banys-Paluchowski, S. Brucker, C. Denkert, Nina Ditsch - Die Onkologie, 2025
Cited by 0 Semantic Scholar

Interdisziplinäres Therapiemanagement von Antikörper-Wirkstoff-Konjugaten beim rezidivierten Ovarialkarzinom

D. Lüftner, K. Stahlhut, M. Untch, G. Konecny - Die Onkologie, 2025
Cited by 0 Semantic Scholar

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial PDF

Gabriel N. Hortobágyi, Aleksandra Łacko, Joohyuk Sohn, F. Melo Cruz, Manuel Ruíz Borrego et al. - Annals of Oncology, 2024
Cited by 79 OpenAlex

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024 PDF

Tjoung‐Won Park‐Simon, Volkmar Müller, Ute-Susann Albert, M. Banys- Paluchowski, Ingo Bauerfeind et al. - Breast Care, 2024
Cited by 17 OpenAlex

Research Topics

Breast Cancer Treatment Studies (28) HER2/EGFR in Cancer Research (14) Advanced Breast Cancer Therapies (13) Cancer Genomics and Diagnostics (7) Cancer Treatment and Pharmacology (7)

Frequent Co-Authors

PE
Peter A. Fasching
8 joint publications
AN
Andreas Schneeweiß
7 joint publications
JE
Jens‐Uwe Blohmer
6 joint publications
CA
Carsten Denkert
6 joint publications
CH
Christian Jackisch
5 joint publications
CH
Christine Solbach
5 joint publications

Affiliations

Goethe University Frankfurt
DE 2025 - 2019
University of St. Gallen
CH 2007 - 2007
Heidelberg University
DE 2025 - 2019
Avera Health
US 2019 - 2019
University Hospital Heidelberg
DE 2025 - 2019

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now